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Summary
Objective: Collagenase-3 is a metalloprotease that plays a role in tissue remodeling and pathological processes including arthritis. The
human gene is transcribed into major (3.0 and 2.5 kb) and minor (2.2/2.0 kb) transcripts, as seen in Northern blot assays. We investigated
the possibility that other transcripts, not detectable by Northern blot, were synthesized as either coding or regulatory RNAs that would
modulate collagenase-3 expression and function/activity.
Design: We screened a cDNA library and total RNA from human chondrocytes by plaque hybridization and RT-PCR, and expressed the
transcripts in a cellular environment. The levels of expression of each transcript in normal and osteoarthritic joint cells and cartilage were
monitored by RT-PCR.
Results: We identified five different collagenase-3 RNA species derived from alternative polyadenylation sites (COL3-APS), internal deletion
(COL3-DEL), alternative splicing (COL3-9B/COL3-9B-2), and different transcription initiation site (COL3-ATS and COL3-ATS-INT). Each
transcript could be translated in a cellular environment. Interestingly, the proteins translated from the COL3-DEL and COL3-9B-2 transcripts
had a modified hemopexin-like domain, suggesting altered collagenolytic activities. The transcript types COL3-APS, COL3-9B-2, and
COL3-ATS were up-regulated in the osteoarthritic samples and expressed in the chondrosarcoma cell line SW1353.
Conclusion: Our data show that the human collagenase-3 gene is subjected to different levels of regulation and constitutes a more complex
system than was originally thought.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Introduction
The regulation of genes implicated in the synthesis and
degradation of the extracellular matrix (ECM) components
during the developmental stage, and later in remodeling
and repair of adult tissue, has to be finely tuned to the
cellular environment. This is needed to ensure proper
balance between normal tissue remodeling and excessive
matrix degradation leading to pathologies, such as, for
example, cancer and osteoarthritis. One group of key
enzymes involved in the turnover of the ECM consists of
collagenases, which are members of the matrix metallopro-
tease (MMP) family. These enzymes share biochemical
properties defined by zinc dependency, secretion in a latent
form, and inhibition by both chelating agents and specific
inhibitors (TIMPs)1. Three types of human collagenases
have been described: collagenase-1 (interstitial colla-
genase or MMP-1), collagenase-2 (neutrophil collagenase
or MMP-8), and collagenase-3 (MMP-13). Although all
three collagenases are active on collagen fibrils, they differ
in their substrate specificity. Collagenase-3 preferentially
cleaves type II collagen and is 5–10 times more active on
this substrate than collagenase-1; collagenase-2 has a
higher specificity for type I collagen and collagenase-1 for
type III collagen2–4. In contrast to collagenase-1, which is
widely distributed in normal and pathological human tis-
sues, the expression of collagenase-3 in normal tissues is
limited to fetal ossification processes5,6 and adult carti-
lage2,3. However, its expression is up-regulated in diseases
such as arthritis2,3,7–10, some malignant tumors11–15, and
chronic ulcer bed wounds16. The enzyme is also associ-
ated with tissue remodeling events17–19. In addition to
degrading types I, II, and III collagens, collagenase-3 has
a telopeptidase activity and the ability to degrade a number
of other components of the ECM including fibronectin,
fibrillin, types IV, IX, X, and XIV collagen, gelatin, and
aggrecan20,21.
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Collagenase-3 is an enzyme of 60 kDa, secreted as
a latent pro-form. It is composed of distinct domains: a
hydrophobic signal sequence necessary for the secretion
of the enzyme, a pro-domain involved in enzyme latency,
which has to be cleaved in order for the enzyme to be
active, a catalytic domain, and a hemopexin-like domain
essential for the collagenolytic activity11. A cellular mech-
anism responsible for collagenase-3 activation has been
proposed by which the enzyme membrane type-1 MMP
(MT1-MMP or MMP-14) and gelatinase A (MMP-2) would
act by forming a proteolytic activation cascade to process
the pro-collagenase-3 to the fully active enzyme22.
Contrary to the other human collagenase genes that are
transcribed into one mature mRNA, human cells express-
ing collagenase-3 synthesize transcripts of 3.0, 2.5, and
2.2/2.0 kb2,11,23–25. These transcripts arise from the use of
different polyadenylation (polyA) sites, but their role and
efficiency of translation have not been evaluated11. Inter-
estingly, the collagenase-3 mRNA size heterogeneity has
been observed only in human cells; it is transcribed into
only one mature mRNA, as detected by Northern blots, in
horse, rabbit, rodent, and dog cells26–28.
The fact that three collagenase-3 transcripts are found in
human cells suggests the presence of potential minor
transcripts, not detectable by Northern blot assays, but
synthesized as either coding or regulatory RNAs that would
modulate collagenase-3 expression and function/activity.
We investigated this possibility by using plaque hybridiz-
ation and reverse transcription-polymerase chain reaction
(RT-PCR) methodologies to screen for variant
collagenase-3 transcripts. We report that the human
collagenase-3 gene is transcribed into variant RNAs that
arise from different polyA and transcription start sites,
out-of-frame internal deletion, and alternative splicing, indi-
cating different levels of regulation for this gene. Further-
more, some of the transcripts are up-regulated in
pathological (osteoarthritic) cells and translated into pro-
teins with functions and activities potentially different from
the original collagenase-3.
Materials and methods
SPECIMEN SELECTION
Human normal cartilage and synovial membranes were
obtained from adults postmortem within 12 h of death
(mean age±SD, 55.2±13.1 years old). The individuals had
no history of joint disease; the tissues were examined
macroscopically and microscopically to ensure that only
normal tissue was used. Human osteoarthritic articular
cartilage (femoral condyles and tibial plateaus) and syn-
ovial membranes were obtained from patients undergoing
total knee arthroplasty (64.6±8.1 years old). All patients
had been evaluated by a certified rheumatologist and had
been diagnosed as having osteoarthritis29. These speci-
mens represented moderate to severe osteoarthritis as
defined according to macroscopic criteria30.
CELL CULTURES
The chondrocytes were released from full-thickness
strips of articular cartilage and synovial fibroblasts from
synovial membranes by sequential enzymatic digestion at
37°C, as previously described2. The cells were seeded at
high density (105 cells/cm2) in tissue culture flasks and
cultured in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco–BRL, Burlington, Canada), supplemented with 10%
heat-inactivated fetal calf serum (FCS; Gibco–BRL) and an
antibiotic mixture (100 U/ml penicillin base and 100 µg/ml
streptomycin base; Gibco–BRL) at 37°C in a humidified
atmosphere of 5% CO2/95% air. Only first-passage cul-
tured chondrocytes were used to ensure their phenotype.
The established human cell lines HepG2 (hepatoblas-
toma), HeLa (cervix adenocarcinoma), and SW1353 (chon-
drosarcoma) were purchased from American Type Culture
Collection (Manassas, VA) and grown at 37°C in DMEM/
10% FCS.
RNA EXTRACTION
Total cellular RNA was extracted with the TRIzol™ re-
agent (Gibco–BRL) according to the manufacturer’s speci-
fications. For the RT-PCR experiments, the RNA was
treated with the DNA-free™ DNase Treatment and
Removal kit (Ambion, Austin, TX) to ensure complete
removal of chromosomal DNA. Total RNA was extracted
directly from human cartilage as previously described31.
EXTRACTION OF HUMAN CHROMOSOMAL DNA
Human synovial fibroblasts were lysed in a buffer con-
sisting of 50 mM Tris pH 8, 100 mM EDTA, 100 mM NaCl,
1% sodium dodecyl sulfate, and 0.5 mg/ml proteinase K.
The mixture was incubated at 65°C for 20 min, extracted
twice with an equal volume of Tris-saturated phenol
(Gibco–BRL) and once with an equal volume of chloroform.
The DNA was precipitated for 30 min at room temperature
with an equal volume of isopropanol and centrifuged. The
DNA pellet was resuspended in sterile water, treated with
0.2 µg/µl RNase A at 37°C for 15 min, and quantitated by
spectrophotometry.
THE cDNA LIBRARY SCREENING
The lambda ZAP Express (Stratagene, La Jolla, CA)
chondrocyte cDNA library was a generous gift from Dr John
A. Di Battista (Osteoarthritis Research Unit, Hoˆpital Notre-
Dame, Centre Hospitalier de l’Universite´ de Montre´al,
Montre´al, Que´bec, Canada). It had been constructed from
polyA+ RNA extracted from six normal and six osteoarthritic
adult human articular chondrocytes, using oligo dT as
primers. The library was screened by both plaque hybrid-
ization and PCR to maximize the recovery of abundant and
rarer collagenase-3 cDNAs.
Screening by plaque hybridization
The cDNA library was screened, as recommended by
Stratagene, with a DIG-labeled collagenase-3 RNA probe,
which consisted of the 500 bp internal ApaI fragment
from the coding region (57–547 bp)11. The RNA probe was
synthesized and labeled with DIG-11-UTP (Roche Diag-
nostics, Laval, Que´bec, Canada) according to the manu-
facturer’s specifications. Detection was performed by
chemiluminescence with the CDP* substrate (Roche
Diagnostics) and exposure to Kodak X-AR5 films (Eastman
Kodak Ltd, Rochester, NY). The autoradiographs were
scanned with the imaging system ChemiImager 4000
(Alpha Innotech Corporation, San Leandro, CA). The ex-
cision of the cloned DNA inserts from the positive plaques
was done as suggested by Stratagene. Plasmid DNA
was purified by passage through a column (Qiagen,
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Chatsworth, CA) and sequenced to identify any homology
to the published collagenase-3 cDNA11 using the BLAST
search32. The Auto Read Sequencing kit (Amersham
Pharmacia Biotech Inc., Piscataway, NJ) was used for the
dideoxyribonucleotide sequencing of double-stranded DNA
template with T7 DNA polymerase.
Screening by PCR
Because of its sensitivity, the PCR method was used to
screen the cDNA bank for less abundant collagenase-3
transcripts. For this assay, one vector-specific primer and
one collagenase-3 primer were used in each reaction (a
vector primer sense and collagenase-3 primer antisense to
amplify the 5′-end of the transcripts and a vector primer
antisense and collagenase-3 primer sense for the 3′-end).
PCR assays were carried out in the Perkin–Elmer DNA
Thermal cycler 480 (Perkin–Elmer, Foster City, CA) for 35
cycles as previously described33, using 1 µl of the chondro-
cyte cDNA library (about 10 000 phages) as template. The
primers were used at a concentration of 200 nM, and their
sequences were derived from the published sequences
of the collagenase-3 open reading frame (ORF)11, 3′-
untranslated region (UTR)11, and promoter region34 (Table
I). The sequences of the pBK-CMV phage-specific primers
BK-2 and BK-3 were obtained from Stratagene (Table I);
these primers flank the restriction sites (EcoRI and XhoI)
into which the cDNA had been cloned.
The PCR products were separated on 1.2% agarose
gels. When required, the DNA fragments were extracted
from the agarose with GFX PCR DNA and Gel Band
Purification kit (Amersham Pharmacia Biotech Inc.) and
cloned directly into the plasmid vector pCR2.1 (Invitrogen,
Groningen, The Netherlands). The cloned fragments were
sequenced in both orientations to identify putative ORFs
and homologies to the collagenase-3 sequence.
REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION
The RT-PCR reactions were carried out in the Perkin–
Elmer DNA thermal cycler 480 as previously described35
with 2 µg of DNase-treated total RNA as substrate. The
assays were run for 35 cycles, and, when required, the
PCR products were purified, cloned, and sequenced as
described in the preceding section.
PROTEIN PRODUCTION IN EUKARYOTIC CELLS
The collagenase-3 DNA fragments obtained from the
cDNA library (COL3-APS and COL3-DEL) and the total
RNA screening (COL3-ATS) were subcloned into the ex-
pression vector pRC/CMV2 (Invitrogen). Plasmid pCOL3-
9B-2 was constructed by ligating two fragments, the 5′-end
fragment containing the ATG signal sequence and the first
half of the collagenase-3 ORF, and the other fragment
containing the second half of the ORF in which the exon 9B
was inserted. The BamHI/XbaI fragment from pCOL3-9B
(second half of the collagenase-3 with exon 9B) was cloned
into the BamHI/XbaI sites of pCRII (Invitrogen); this plas-
mid was linearized with BamHI into which the BamHI
fragment from pCOL3-APS (first half of the ORF) was
cloned. The resulting plasmid was digested with HindIII and
cloned into the HindIII site of pRC/CMV2; this plasmid
contains the whole original sequence of collagenase-3 with
exon 9B. The sequencing of the plasmid constructs con-
firmed the identity and orientation of the cloned DNAs. The
Table I
PCR primers
Primer Sequence Position
Collagenase-3 promoter
AP-1 5′-TAAGTGATGACTCACCATTGC-3′ −43 to −63 (S)
PEA-3 5′-AGTGACTAGGAAGTGGAAACC-3′ −70 to −90 (S)
GSP-12 5′-GAGACCCTGCTGAAACAAGA-3′ −182 to −201 (S)
GSP-11 5′-CGTTTATTTTGCCAGATGGG-3′ −206 to −225 (S)
GSP-8 5′-CTCTCTGCTTCTTCCCACAGTATC-3′ −243 to −266 (S)
Collagenase-3 ORF
3 5′-AGATGCATCCAGGGGTCCT-3′ 3 to 21 (S)
1 5′-CTTAGAGGTGACTGGCAAAC-3′ 232 to 251 (S)
15 5′-AGGAAACATGAGTGCTCCAG-3′ 711 to 730 (AS)
5 5′-TCCCTTGATGCCATTACCAG-3′ 869 to 888 (S)
21 5′-CTTCCCAGGAATTGGTGAT-3′ 1273 to 1291 (S)
22 5′-GGAATTTGCTGGCATGACGCG-3′ 1385 to 1405 (AS)
Collagenase-3 3′-UTR
12 5′-TACCCCAAATGCTCTTCAGG-3′ 1449 to 1468 (AS)
7 5′-CTTTTATGTATGGCTCTCCC-3′ 1837 to 1856 (AS)
Collagenase-3 exon 9B
211-2 5′-CTGTAATCCCAGCTACTCC-3′ (AS)
Vector pBK-CMV
BK-2 5′-GGGAACAAAAGCTGGAGCTC-3′ 1141 to 1122 (S)
BK-3 5′-ATTGGGTACACTTACCTGG-3′ 1016 to 998 (AS)
GAPDH
1 5′-CAGAACATCATCCCTGCCTCT-3′ (S)
2 5′-GCTTGACAAAGTGGTCGTTGAG-3′ (AS)
The sequences of the primers used in this study were derived from the published sequences of the human collagenase-3 promoter34, ORF,
and 3′-UTR11, and exon 9B (this study). The sequence of the vector pBK-CMV was obtained from Stratagene. The numbers refer to their
position in the published sequence. The primers were synthesized in the sense (S) or antisense (AS) orientation and were routinely used at
a concentration of 200 nM in all the PCR reactions.
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plasmids were transfected into chondrocyte HeLa and
HepG2 cells to evaluate the protein-coding potential of
the different ORFs contained in the collagenase-3 DNA
fragments.
TRANSIENT TRANSFECTION ASSAYS
Transfections were carried out with the calcium phos-
phate co-precipitation method as previously described34.
The cell lines HeLa and HepG2 were routinely used, as
these cells do not produce endogenous collagenase-3.
Briefly, cells were seeded at 50% (cell lines) or 90%
(chondrocytes) confluency and transfected with a DNA–
calcium preparation, consisting of 125 mM CaCl2 and
10 µg of the plasmid constructs. The cells were incubated
for 48 h in DMEM containing 0.5% FCS in a humidified
atmosphere of 95% air/5% CO2 at 37°C. After the incu-
bation, the culture supernatants were collected and mixed
with a loading buffer for a final concentration of 62.5 mM
Tris–HCl, pH 6.8, 2% w/v SDS, 10% glycerol, 5%
β-mercaptoethanol, and 0.05% bromophenol blue. The
cells were lysed directly in the same loading buffer.
WESTERN IMMUNOBLOTTING
Total proteins from the transfected cells were electro-
phoresed in 12% SDS-polyacrylamide gels, transferred
electrophoretically onto a nitrocellulose membrane
(Hybond-C Extra, Amersham Pharmacia Biotech Inc.), and
processed for Western immunoblotting as previously de-
scribed2. The primary antibody (anti-human collagenase-3)
was a mouse monoclonal IgG (1:10 000 dilution), gener-
ously provided by Pfizer Central Research (Groton, CT)2.
The secondary antibody was an anti-rabbit IgG horseradish
peroxidase conjugate (1:25 000 dilution, Pierce, Rockford,
IL). Detection was performed by chemiluminescence with
the SuperSignal® ULTRA Chemiluminescent substrate
(Pierce) according to the manufacturer’s specifications.
ELISA COLLAGENASE-3
Collagenase-3 levels in the culture medium and cell
lysates were quantified by a specific ELISA assay
(Amersham Pharmacia Biotech Inc.) recognizing both the
pro- and active forms of the enzyme.
DATA ANALYSIS
Values are expressed as mean±S.E.M. When appropriate,
statistical significance was assessed using the two-tailed
Student’s t-test and a P value <0.05 was considered
significant.
Results
PLAQUE HYBRIDIZATION OF THE cDNA LIBRARY: IDENTIFICATION
OF COLLAGENASE-3 TRANSCRIPTS WITH ALTERNATIVE
POLYADENYLATION SITES (COL3-APS)
The human chondrocyte cDNA bank was screened by
plaque hybridization with the collagenase-3 RNA probe.
Two positive plaques were obtained, and their cDNA inserts
(COL3-APS-1 and COL3-APS-2; Fig. 1) were sequenced.
The 5′-end of the clone COL3-APS-1 starts 11 bp upstream
of the ATG start codon and the 3′-end stops at bp 1851 of
the published sequence11; clone COL3-APS-2 also starts
11 bp upstream of the ATG start codon and stops at bp
1927. Although the transcription start site of each clone is
similar to the one previously reported34, the polyA site
differs, the 3′-UTR of the original sequence stopping at bp
2690. The COL3-APS clones contain an ORF of 1416 bp
with the potential to produce a protein identical in amino
acid sequence (471 amino acids) to the original
collagenase-3.
PCR SCREENING OF THE cDNA LIBRARY: IDENTIFICATION OF
COLLAGENASE-3 TRANSCRIPTS WITH AN OUT-OF-FRAME
DELETION (COL3-DEL) AND WITH AN EXTRA EXON (COL3-9B)
The cDNA bank was screened by PCR in order to identify
the presence of less abundant collagenase-3 mRNA spe-
cies, such as splice variants. The start sites at the 5′-end of
the cDNAs were identified using the vector primer BK-2 and
the antisense collagenase-3 primer 7; the 3′-ends of the
cDNAs were obtained using the sense collagenase-3
primer 3 and the BK-3 vector primer. This screening pro-
cedure led to the amplification of DNA fragments that were
cloned and sequenced.
Clone COL3-DEL
The clone COL3-DEL (Fig. 1) was obtained from a PCR
reaction with the collagenase-3 sense primer 3, and the
vector antisense primer BK-3. COL3-DEL contains the
same ATG start codon as in the original sequence and ends
at bp 1929 in the 3′-UTR, a polyA site similar to those of the
COL3-APS clones. The sequence of COL3-DEL is identical
to the published collagenase-3 cDNA sequence11, except
for a major internal deletion of 387 bp (bp 1142–1528). The
deletion encompasses part of the hemopexin-like domain
(the last 92 amino acids), the TAA stop codon, and the first
108 bp of the 3′-UTR region. The deletion introduces four
new amino acids (N, K, L, Q) followed by a new stop codon
from the original 3′-UTR sequence. The sequences of the
boundaries of the deleted region (AAGTT/aagaa{ctgtg/
AACAA) do not match consensus splice sites36. The event
leading to the formation of this deletion is still undeter-
mined, but it does not seem to be due to the splicing of a
known intron; the deletion starts at bp 1142, halfway
between the splice sites of introns 7 and 8, and ends at bp
1528 in the 3′-UTR sequence. Computer splice prediction
analysis with the program Spliceview37 of the region
around the deletion did not yield potential donor or acceptor
splice sites. COL3-DEL has an ORF with the potential to
code for a 383 amino acid protein (43.5 kDa). This protein
would have an identical N-terminus as the original
collagenase-3, including the signal sequence (the first 19
amino acids) and activation sites4.
Clone COL3-9B
The PCR screening of the cDNA bank led to the identifi-
cation of another clone, COL3-9B. This clone was obtained
with vector primer BK-2 and collagenase-3 primer 7 (Fig.
1). The 5′-end of the fragment starts at bp 753 of the
original sequence11 and extends into the 3′-UTR up to
primer 7 (bp 1856). The sequence of COL3-9B revealed
the presence of an additional exon of 118 bp (designated
exon 9B) at the splice junction of intron 9 (bp 1319–1320).
Because of its location, the origin of the new exon was
thought to result from a sequence present in intron 9, an
intron that normally splices out entirely. To verify this
hypothesis, we cloned and sequenced intron 9. The
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genomic DNA extracted from human synovial fibroblasts
was used as substrate in PCR reactions with primers 21
and 22, the sequences of which flank intron 9. A fragment
of 1.3 kb, corresponding to the reported size of intron
9, was obtained, cloned into vector pCR2.1, and was
sequenced. The sequencing data showed that the 5′-
and 3′-termini matched the partial sequence published by
Pendas et al.38. A sequence identical to exon 9B was found
in intron 9 starting at bp 411 from the 5′-end of the intron.
The analysis of the splice sites revealed differences in the
splice sites normally used. When exon 9B is absent, intron
9 is spliced at the sites AATG/gtaag and atag/GTTA; when
exon 9B is present, the splicing occurs at the non-
conventional sites AATGG/taag and caga/GTCT. A search
through the DNA databank has identified the exon 9B
sequence as homologous (104/118 bp) to one segment of
the Sx subfamily of Alu elements (Genbank accession
number U14574), but in the inverse orientation relative to
exon B (Fig. 2).
It is possible that the unusual start site of COL3-9B could
have resulted from premature termination during the
construction of the cDNA bank. To verify this eventuality,
PCR reactions were carried out with total RNA using
collagenase-3 primers 3 and 1 (sense) and exon 9B primer
211-2 (antisense). The amplification of fragments would
indicate the presence of RNA transcripts with a 5′-end
extending upstream of bp 753 and the presence of a longer
ORF. Such fragments were amplified, and their sequences
were homologous to the collagenase-3 sequence. In con-
trast, no fragments could be amplified from the cDNA bank
using the same sets of primers. These results suggest that
clone COL-9B does not represent the whole transcript and
that the mRNA with exon 9B has the same start codon as
the original collagenase-3. It was not possible to amplify the
whole ORF containing exon 9B with primers 3 and 7,
probably because of its low abundance in total RNA com-
pared with the high levels of the original collagenase-3,
which would be amplified preferentially. To obtain the whole
Fig. 1. Schematic representation of collagenase-3 DNA clones. COL3: schematic representation of the published collagenase-3 cDNA
downstream of the promoter sequence11,34. The dark box represents the proximal promoter sequence, the open box, the ORF, and the
dotted box, the 3′-UTR. The letters and numbers above the arrows identify the primers used to identify the new collagenase-3 transcripts;
→ refers to primers synthesized in the sense orientation and ← refers to primers synthesized in the antisense orientation. ATG: translation
start codon, and TAA translation stop codon. The locations of introns 1 and 9 (circled) are indicated by vertical thick lines. COL3-APS: clone
obtained from the chondrocyte cDNA bank by plaque hybridization. COL3-DEL: clone obtained from the chondrocyte cDNA bank by PCR
using primers 3 (collagenase-3) and BK-3 (phage vector); the deletion (387 bp) is indicated by a bent line. COL3-9B and COL3-9B-2: clone
COL3-9B was obtained from the chondrocyte cDNA bank by PCR using primers BK-2 (phage vector) and 7 (collagenase-3); the location of
exon 9B (118 bp) is indicated by an inverted triangle at the splice site on intron 9; clone COL3-9B-2 was constructed from clones COL3-APS
and COL3-9B as described in Materials and Methods. COL3-ATS: clone obtained from screening total RNA by RT-PCR using the primers
GSP-11 and 7. COL3-ATS-INT: clone obtained from screening total RNA by RT-PCR using the primers GSP-11 and 7; the presence of intron
1 is indicated by an inverted triangle. The numbers at the far right in parentheses represent the number of amino acids (a.a) deduced from
the DNA sequence.
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exon 9B-containing ORF, we have used the ‘cut and paste’
strategy described in Materials and Methods to construct
clone COL3-9B-2. Clone COL3-9B-2 has an ORF for a
protein of 489 amino acids with the same signal sequence
and activation sites as the original collagenase-3. Because
of the presence of the new exon, the reading frame is
changed starting at the beginning of exon 9B, and a TGA
stop codon is located at bp 1354 of the original
collagenase-3 sequence (Figs. 1 and 3). Because of the
premature termination of COL3-9B, we have used COL3-
9B-2 in all subsequent experiments.
RT-PCR SCREENING OF TOTAL RNA: IDENTIFICATION OF
COLLAGENASE-3 TRANSCRIPTS DERIVED FROM AN ALTERNATIVE
TRANSCRIPTION START SITE (COL3-ATS AND COL3-ATS-INT)
One way of regulating gene expression is through the
use of alternative transcription start sites and different
promoters, the activities of which might be induced by
different cellular environments. To search for transcription
start variants, total RNA from osteoarthritic chondrocytes
was used as substrate in RT-PCR assays, with primers
derived from the promoter sequence (GSP-8, GSP-11,
GSP-12, PEA-3, and AP-1; sense orientation) and the
published coding sequence (15, 12, and 7, antisense
orientation) (Table I). Because the sequence corresponding
to primers GSP-8 to AP-1 is not included in the reported
5′-UTR11,34, the amplification of fragments would reveal the
presence of transcripts with different transcription initiation
sites. Two fragments, COL3-ATS and COL3-ATS-INT (Fig.
1), were amplified using the sense promoter primer GSP-11
and the antisense ORF primer 12. No fragment could be
amplified with the sense primer GSP-8 located upstream of
GSP-11, suggesting that the transcripts are likely to start in
the region between bp 242 and 225. The screening of the
cDNA bank with primers GSP-11 and 12 did not yield any
fragment. It is possible that, as seen with clone COL3-9B,
there was a premature termination during the construction
of the cDNA library.
The sequencing of clones COL3-ATS and COL3-ATS-
INT showed that they comprised a continuous fragment
consisting of the first 225 bp of the proximal promoter
region, the ORF of the collagenase-3, and 48 bp of its
3′-UTR up to primer 12 (Fig. 1). Both fragments were
identical except for the presence in COL3-ATS-INT of the
sequence corresponding to the collagenase-3 intron 1
(splice site between bp 124 and 125)38. Clone COL3-ATS
has the same ORF as the original collagenase-3 sequence,
with the exception of an extended 5′-UTR of about 200 bp.
Clone COL3-ATS-INT has retained intron 1 and may be
derived from an unprocessed RNA. If this RNA is translated
from the same ATG as COL3-ATS, the presence of intron 1
will change the reading frame and give a very short ORF
with the stop codon at bp 468 (Fig. 1). If the intron is spliced
out during the transcription/translation processes, the orig-
inal ORF will be recovered with its regular stop codon at bp
1418, and a protein identical to the original collagenase-3
will be synthesized.
PROTEIN PRODUCTION FROM THE COLLAGENASE-3 TRANSCRIPTS
The potential for each type of collagenase-3 transcript to
be translated in a cellular environment was assayed by
cloning the cDNAs COL3-APS, COL3-DEL, COL3-9B-2,
COL3-ATS, and COL3-ATS-INT into the expression vector
pCR/CMV2. HeLa, HepG2 (Fig. 4) and human osteo-
arthritic chondrocytes (not illustrated) were transfected with
the constructs, and collagenase-3 production was moni-
tored in the protein lysates and culture media by Western
immunoblots and ELISA. As shown in Fig. 4, COL3-APS,
which contains the same ORF as the published sequence,
produces a protein that is secreted in the culture medium;
Fig. 2. Sequence homology between exon 9B and the Alu-Sx element. The exon 9B sequence (upper strand) was aligned with the Alu-Sx
sequence (lower strand, Genbank accession number U14574). The Alu sequence is shown in the inverse orientation. Homology (indicated
by vertical lines) was found for 104/118 bp.
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the protein is also found in the cell lysate. The COL3-APS
protein has the same molecular weight as the original
human collagenase-3 (471 amino acids) and migrates at
the same location. The COL3-DEL construct produces a
protein of 383 amino acids. The smaller size compared with
the original collagenase-3 protein results from the internal
deletion present in clone COL3-DEL. This protein is found
in both the cell lysate and culture medium, but at barely
detectable levels. The protein translated from clone COL3-
ATS-INT behaves as the original collagenase-3. This pro-
tein has the same molecular weight, is found in the cell
lysate, and is secreted, suggesting that the intron has been
spliced out before translation. Clone COL3-ATS is trans-
lated into a protein that is identical in size and migration
rate as the original collagenase-3. This was not unexpected
since this clone contains the same ORF as the original
sequence—the only difference being a longer 5′UTR. By
Western blot, this protein is detected only in the cell lysate
and not in the culture medium, but quantification by ELISA
in the culture medium of HeLa and HepG2 cells revealed
that the protein was secreted, but was present at low levels.
There was an average production of 315 ng COL3-ATS per
microgram of total protein compared with 4710 ng COL3-
ATS-INT per microgram of total protein. The COL3-9B-2
construct produces a protein of 489 amino acids. The larger
molecular weight when compared with the original
Fig. 3. Predicted amino acid sequence of clone COL3-9B-2 (accession number AY256443). The nucleotide and amino acid sequences of
original collagenase-311 are shown in light characters. The presence of exon 9B changes the reading frame and the new sequence is shown
in bold characters; the location of the new stop codon TGA(*) is indicated.
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collagenase-3 reflects the presence of exon 9B and
possibly an increased glycosylation of the protein. This
protein is recovered in the cell lysate at levels similar to or
higher than those of the COL3-APS clone. This protein is
released into the culture medium of HepG2 cells (Fig. 4)
and human chondrocytes (not illustrated) but not HeLa
cells. It is possible that the COL3-9B-2 protein is secreted
into the culture medium of HeLa cells, but at levels un-
detectable by the Western blot as seen with clone COL3-
ATS. We could not quantify the protein by ELISA because
the antibody used in this assay does not recognize the
COL3-9B-2 protein.
As also shown in Fig. 4, we detected a protein of about
35 kDa in all the cellular lysates that were tested. At first, it
was thought that this protein represented a collagenase-3
variant or a degradation product. To test this hypothesis,
HepG2 cytosolic proteins were extracted, migrated in
duplicate 2-D electrophoresis gels, and transferred to
PDVF membranes. One membrane was stained with
coomassie blue, while the other one was processed for
immunoblotting with the MMP-13 antibody. The antibody
recognized one protein on the immunoblotted membrane,
and the corresponding spot on the coomassie blue-stained
membrane was excised and processed for sequencing.
The amino acid sequence identified, surprisingly, this
protein as an aldolase.
DIFFERENTIAL EXPRESSION OF THE COLLAGENASE-3
TRANSCRIPTS
The cDNA bank that we have used to screen the
collagenase-3 clones had been constructed from RNA
extracted from both normal and osteoarthritic human adult
chondrocytes. The screening methods earlier described do
not discriminate gene expression between normal and
osteoarthritic samples. To evaluate any differential expres-
sion of the transcripts, we have isolated total RNA from
chondrocytes (five normal and five osteoarthritic), synovial
fibroblasts (four normal and four osteoarthritic), and from
the human cell line SW1353, which is derived from a
chondrosarcoma and known to produce collagenase-3. In
addition, RNA was also extracted directly from human
normal (N5) and osteoarthritic (N5) cartilage. The pres-
ence and relative abundance of the transcripts were deter-
mined by RT-PCR with the following sets of primers to
differentiate the transcripts: primers 5 and 7 amplify a
fragment of 988 bp (COL3-APS) and 601 bp (COL3-DEL),
primers 5 and 211-2 a fragment of 569 bp (COL3-9B-2),
and primers GSP-12 and 15, a fragment of 949 bp (COL3-
ATS) and 1041 bp (COL3-ATS-INT). The housekeeping
gene GAPDH was used as a control of amplification with
each sample. Arbitrary values for each transcript in a given
specimen were determined by densitometry and expressed
as the ratio of the collagenase-3 transcript over the GAPDH
value.
Primers 5 and 7 (Fig. 5, top panel) were used in RT-PCR
reactions to detect the presence of transcripts COL3-APS
(988 bp amplified fragment) and COL3-DEL (601 bp frag-
ment). When the cDNA bank was used as substrate, the
two major bands corresponding to COL3-APS and COL3-
DEL were amplified along with a minor band migrating at
about 1.1 kb that corresponds to the presence of clone
COL3-9B-2. In contrast, only the fragment corresponding to
COL3-APS (988 bp) was amplified from the normal and
Fig. 4. Expression of the collagenase-3 transcripts in a cellular environment. Plasmid vector pRC/CMV2 without (empty vector) and with the
different collagenase-3 fragments COL3-APS, COL3-DEL, COL3-9B-2, COL3-ATS, COL3-ATS-INT were transfected into HeLa and HepG2
cells by the calcium co-precipitation method. The cells were incubated for 48 h in 0.5% FCS, after which the culture media were collected
and the cells were lysed in the loading buffer as described in Materials and Methods. The samples (20 µg proteins) were run in 12%
polyacrylamide gels. Collagenase-3 production in the cell lysates and culture media were determined by Western blotting. rhCOL3: human
recombinant collagenase-3 protein (10 ng). The arrow heads indicate the location of the COL3-DEL protein and the arrow, the aldolase
protein recognized by the collagenase-3 antibody.
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osteoarthritic chondrocytes, synovial fibroblasts, and the
cell line SW1353. The fragment indicative of COL3-DEL
(601 bp) was present at very low levels only in RNA
samples directly extracted from cartilage. Of the five RNAs
directly extracted from normal cartilage, only one specimen
was positive for COL3-APS; in contrast, four of the five
RNAs extracted from osteoarthritic cartilage were positive.
The presence of COL3-APS was detected in all the cul-
tured chondrocytes (normal and osteoarthritic), all the
osteoarthritic synovial fibroblasts, and three of the four
normal synovial fibroblast specimens. Comparisons be-
tween the normal and osteoarthritic specimens revealed an
increase in the abundance of the COL3-APS fragment in
the latter samples (chondrocytes, 0.48±0.03 vs 1.02±0.14,
P<0.005; synovial fibroblasts, 0.43±0.15 vs 0.67±0.04); the
statistical significance was reached only for the chondro-
cytes.
Primers 5 and 211-2 were used to detect the presence of
transcripts with exon 9B. As illustrated in Fig. 5, a DNA
fragment of the expected molecular weight of 569 bp was
amplified when the cDNA bank was used as substrate. The
same fragment was also amplified from all the chondro-
cytes (normal and osteoarthritic) that were tested, as well
as from SW1353, although it was found at a very low level
in the latter sample. The fragment was detectable in three
of the four normal and osteoarthritic synovial fibroblasts. No
fragment could be amplified from RNA directly extracted
from normal or osteoarthritic cartilage. However, a second
larger DNA fragment of about 750 bp was sometimes
amplified, but does not appear to be a specific
collagenase-3 fragment. The COL3-9B-2 transcripts were
also present in a greater abundance in the osteoarthritic
samples, and statistical significance was reached only with
the chondrocytes (chondrocytes, 0.23±0.03 vs 0.33±0.02,
P<0.03; synovial fibroblasts, 0.15±0.05 vs 0.30±0.10).
Finally, the presence of transcripts with an alternative
transcription start site was detected with the primer pair
GSP-12 and 15. A fragment with the molecular weight
expected for COL3-ATS (949 bp) was amplified from all
the cultured normal and osteoarthritic chondrocytes,
Fig. 5. Differential expression of the collagenase-3 transcripts by PCR. The relative abundance of the different collagenase-3 transcripts was
measured by RT-PCR using as substrate DNase-treated total RNA extracted from the cell line SW1353, normal (S-N) and osteoarthritic
synovial fibroblasts (S-OA), normal (C-N) and osteoarthritic chondrocytes (C-OA), RNA directly extracted from normal (CART-N) and
osteoarthritic cartilage (CART-OA) and the cDNA bank. The primers used in the PCR reactions to discriminate the transcripts were 5 and 7
for the COL3-APS and COL3-DEL transcripts (expected fragment sizes of 988 and 601 bp, respectively), 5 and 211-2 for the COL3-9B-2
transcripts (fragment size of 569 bp), GSP-12 and 15 for the COL3-ATS and COL3-ATS-INT transcripts (fragment sizes of 949 and 1041 bp,
respectively). Primers for the amplification of the housekeeping gene GAPDH (fragment size of 319 bp) were tested as a control. Values are
expressed as mean±S.E.M.; P values were determined by two-tailed Student’s t-test. The left panels are representative RT-PCR assays for
each transcript type and the right panels represent histograms illustrating the mean±S.E.M. of five (chondrocytes and cartilage) and four
(synovial fibroblasts) independent samples. Arrowhead: non-specific amplified fragment of about 750 bp.
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osteoarthritic synovial fibroblasts as well as from SW1353.
The fragment was amplified from three of the four normal
synovial fibroblast specimens. No fragment was detected
with the RNA extracted from cartilage and with the cDNA
library. Comparison between the normal and osteoarthritic
samples also revealed significantly more COL3-ATS tran-
scripts in the osteoarthritic chondrocytes and synovial fibro-
blasts compared with normal specimens (chondrocytes,
0.38±0.06 vs 0.88±0.09 P<0.003; synovial fibroblasts,
0.31±0.12 vs 0.62±0.04, P<0.05). The fragment corre-
sponding to the COL3-ATS-INT could not be detected in
any of the samples that were tested.
Discussion
Many eukaryotic genes constitute complex transcrip-
tional units that produce several RNA molecules from one
single gene. Overall, gene expression can be modulated by
the use of different promoters, by alternative splicing of
pre-mRNAs, and by the use of different polyA sites. All of
these events ultimately yield regulatory and coding RNAs
with the potential to produce proteins with specific roles or
activities, depending on tissue type, developmental stage,
or pathology. The biological significance of alternative splic-
ing is becoming more evident, as more genes have been
discovered to use alternative splicing as a mechanism to
generate protein diversity from a limited number of genes.
Well-known models include the genes coding for fibro-
nectin39,40, the cysteine protease cathepsin B41,42, and
the insulin-like growth factors43. Because of the role of
collagenase-3 in developmental and pathological pro-
cesses, its transcription and translation are likely to be the
target of such regulatory events. In this study, we show that
the collagenase-3 gene is transcribed into different species
of RNA, which are up-regulated in osteoarthritic samples
and are translated into proteins with functions and activities
in pathological samples potentially different from the
original collagenase-3.
It could be argued that these transcripts are the result of
artifacts produced during the making of the cDNA library or
the RT-PCR assays. However, the transcripts are gener-
ated in different cell types (synovial fibroblasts, chondro-
cytes, the cell line SW1353), in the majority of the
specimens that were tested, and they are up-regulated in
the osteoarthritic specimens compared with normal. It is
unlikely that the same artifacts would consistently be repro-
duced in all these cases. The expression of the transcripts,
both major and minor, seems to be up-regulated in the
cultured cells when compared with the levels obtained from
the RNA directly extracted from cartilage. Even though the
COL3-DEL, COL3-9B-2, and COL3-ATS transcripts repre-
sent a small percentage of the total transcript population in
the adult cells that were tested, they may still have a role
to play in the overall regulation of the collagenase-3 gene,
not only in the adult tissues, but also in the develop-
mental processes taking place in fetal tissues. Indeed,
collagenase-3 is expressed during human fetal ossification
and later in life in destructive joint diseases; the
collagenase-3 isoforms, even present at low levels, may
have different activities and roles to play in the matrix
remodeling associated with these processes.
The first type of collagenase-3 transcripts, COL3-APS,
was generated from the use of different polyA sites, a
common RNA processing step. The polyA tail plays a role in
the stability and translatability of the RNA44–46. Northern
blots of RNA extracted from human cells have previously
revealed the presence of two major transcripts of 2.5 and
3.0 kb and minor ones of 2.2/2.0 kb2,11. Freije et al.11 have
extracted RNA from human breast carcinomas and have
shown that the transcript sizes are the result of the use of
different polyA site; a 3′-UTR probe hybridized to the 3.0 kb
transcript but not to the others. We have obtained similar
results with RNA extracted from human chondrocytes with
our probe spanning 822 bp in the collagenase-3 3′-UTR (bp
1837–2658, personal observation). As the size of the cDNA
inserts in clones COL3-APS was about 1.8 kb, the clones
may represent the 2.2/2.0 or 2.5 kb transcripts depending
on the size of the polyA tail. The different polyA sites do not
seem to influence the overall stability or inducibility of the
3.0 and 2.5 kb RNAs, as they are recovered in equal
amounts from the cells and are modulated similarly by
different cytokines and growth factors2,25,47–52. The role of
different polyA sites in the collagenase-3 transcription and
the efficiency of translation for each transcript remain to be
determined. The COL3-APS transcript is identical in coding
sequence and transcription initiation site to the original
collagenase-3 sequence11. This transcript, as expected,
is translated into a protein identical to the original
collagenase-3 protein and is secreted into the medium.
This protein likely represents the original collagenase-3
protein and should retain all its biochemical properties2–
4,20,21
. As expected, the COL3-APS transcript was the most
common transcript to be recovered from all the tested
samples and was found in greater abundance from the
samples originating from osteoarthritic specimens.
Another type of RNA variant found in this study was
COL3-DEL, which is characterized by an out-of-frame
deletion, located in the region of DNA coding for the
hemopexin-like domain. The deletion removed part of
the hemopexin-like domain, but the clone still retains the
sequences coding for the signal peptide and the zinc-
binding domain. Interestingly, our clone resembles the
recombinant human C-terminal truncated form of the pro-
collagenase-3 that was constructed in vitro and expressed
by Knauper et al.20. The deletion of their truncated enzyme
spanned amino acids 249–451 compared with the COL3-
DEL protein, which lacks amino acids 380–471. Knauper
et al.20 have shown that the kinetics of activation and the
specific activities of their truncated enzyme were not af-
fected, but that it failed to bind to and cleave native triple
helical types I and II collagens. The association rates
of the truncated enzyme with TIMP-1 and TIMP-3, but
not TIMP-2, were significantly reduced as well. On the
other hand, the truncated enzyme, like the original
collagenase-3, still retained the capacity to hydrolyze the
large tenascin C isoform, fibronectin, and types IV, IX, X,
and XIV collagens. The COL3-DEL protein may share the
same biochemical properties as the truncated enzyme of
Knauper et al.20. The COL3-DEL transcript is translated
into a secreted protein. However, its abundance seems
very low when compared with the level of expression of the
other transcripts. This may reflect low expression, reduced
stability of the protein, or more likely, a poor recognition of
this smaller protein by the antibody. As the COL3-DEL
protein is as well not recognized by the ELISA antibody, a
quantification of the protein could not be done. We have not
detected the COL3-DEL transcript in the cultured cells
(chondrocytes, synovial fibroblasts, and SW1353), possibly
because of the low abundance of this transcript; the
primers used to amplify this fragment are the same ones
that will amplify the major collagenase-3 transcript and the
latter will be amplified preferentially. This may also be
the reason why we detect the COL3-DEL transcripts only in
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the RNA from cartilage, as the levels of the COL3-APS
transcripts in these samples are less abundant.
The third type of collagenase-3 transcript, COL3-9B-2,
was derived from an alternative splicing event. Alternative
splicing is a RNA processing event capable of generating
multiple species of mature RNA. These RNAs, in turn, may
have different translation efficiencies or may be translated
into proteins that differ in their tissue distribution, function,
or cellular localization41,53,54. Although it could be argued
that the COL3-9B-2 transcript represents a partly pro-
cessed RNA, this would seem unlikely as the patterns of
expression of COL3-9B-2 and COL3-APS are similar be-
tween the different cell types. COL3-9B-2 is characterized
by the presence of an additional small exon of 118 bp, exon
9B, located at the splice junction of intron 9. A search
through the DNA databases indicated strong homology
between exon 9B and part of the Alu-Sx element. Alu
elements55,56 are regularly found in the introns of most
protein-coding genes; in the case of collagenase-3, we
have found a copy in intron 9. One mechanism by which an
Alu element can be introduced into a protein-coding region
is by the splicing of an intronic Alu sequence into the coding
region of the mRNA (Alu cassette), a mechanism that
seems to have occurred in COL3-9B-2. There have been
reports of Alu cassettes spliced into the coding regions of
the host mRNAs, and such events are a source of protein
variability55. In the case of the COL3-9B-2 transcript, the
insertion of the Alu cassette occurs near the C-terminal part
of the hemopexin-like domain and alters the reading frame
of the main ORF, resulting in the replacement of the last 32
amino acids with 50 other residues. Such a modified
collagenase-3 protein would probably retain the biochemi-
cal properties of the original collagenase-3 relating to its
activation and catalytic activities; however, the binding and
cleavage of the collagen fibrils may be affected, since part
of the hemopexin-like domain is modified in the COL3-9B-2
protein. Alternative splicing involving an intronic exon has
been described with another collagenase, collagenase-257.
This splice variant had a 91 bp insert between the codons
for amino acids 34 and 35 and the potential to code for a
444 amino acids protein, which lacks the secretory signal
peptide of the original collagenase. In this case, it has not
been reported if the extra exon was derived from an Alu
element.
The COL3-9B-2 transcript is translated into a secreted
protein. As for the COL-DEL protein, the COL3-9B-2 protein
is not recognized by the ELISA antibody and thus could not
be quantitated. The COL3-9B-2 transcript is found in the
cultured chondrocytes, synovial fibroblasts, and SW1353,
but not in the RNA directly extracted from cartilage, possi-
bly because of the low levels of the RNA variant. This
transcript is also up-regulated in osteoarthritic cells; thus,
there may be, in osteoarthritic cartilage, more than one type
of collagenase-3 protein if the COL3-DEL and COL3-9B-2
proteins are also expressed in vivo. All three proteins are
secreted and share the same catalytic domain, but their
activities on cartilage type II collagen, as well as the
capacity of the TIMP molecules to inhibit their activities,
would be different.
The last type of transcripts is represented by COL3-ATS
and COL3-ATS-INT. These transcripts are the result of two
different regulatory events: both share a different transcrip-
tion initiation site leading to a longer 5′-UTR (about 220 bp
instead of 11–28 bp upstream of the ATG start codon),
and COL3-ATS-INT differs from the other clones by the
presence of intron 1, which is normally spliced out. The
presence of a longer 5′-UTR in COL3-ATS seems to affect
collagenase-3 production. The COL3-ATS protein is recov-
ered in low amounts in the cell lysate and is detectable in
the culture medium only by ELISA. It is unlikely that the
3′-UTR plays a role in the translation efficiency, as all our
collagenase-3 clones have basically the same 3′-UTR
sequence. One possibility is that the longer 5′-UTR binds
some factor that would regulate translation. For example, it
has been reported that p53 binds the 5′-UTR of cdk4 RNA
and inhibits its translation58, although the precise mech-
anisms of inhibition were not elucidated. The DNA con-
sensus binding site of p53 consists of two copies of the
sequence PuPuPu (A/T)(T/A)PyPyPy separated by
0–13 bp. There is one copy of this sequence in the leader
sequence of the COL3-ATS clones, but its functionality is
still unknown. Alternatively, the presence of short distal
ORFs in the leader sequence may affect translation of the
main ORF. Such a regulation has been described for the
gene coding for seprase, an integral membrane gelatinase.
The gene is transcribed into two different mRNAs; one
mRNA has a longer 5′ leader sequence that harbors two
upstream ORFs that inhibit seprase expression from the
major ORF59. There are two ORFs upstream of the main
ATG start codon in the 5′-UTR of COL3-ATS and COL3-
ATS-INT. The first ORF is short (105 bp) and ends 127 bp
upstream of the ATG start codon. The second ORF is
161 bp long, it starts 79 bp upstream of and spans the main
ATG start codon. Such a transcript could interfere with
translation from the major ORF. It remains to be determined
whether the lower expression of COL3-ATS compared with
the original collagenase-3 is the result of inhibitory factors
or the presence of short ORFs.
One unexpected result was that the clone COL3-ATS-
INT, which has a 5′-UTR identical to that of COL3-ATS, is
translated more efficiently, although not to the extent of the
original collagenase-3. There may be an additional element
in the first intron that would counteract the low expression
seen with clone COL3-ATS, before eventually being spliced
out. The first intron has been shown in several systems to
regulate transcription. There have been reports of binding
sites and enhancer elements in the first intron of several
genes: human Sox960, types II61, X62, and XI collagen63.
Also, p53 response elements have been located in the first
intron of the murine and human bax gene64 and the bovine
mimecan gene65. Similarly, the collagenase-3 intron I could
also play a role in gene expression. The COL3-ATS-INT
transcript may represent an intermediate RNA molecule.
The first intron may be the last one to be spliced because of
the need for the regulatory elements present in the intron.
The transcription start site of the collagenase-3 gene has
been previously mapped at 22 bp34 and 28 bp38 upstream
of the ATG start codon, using the primer extension method.
It is possible that the start site responsible for the gener-
ation of COL3-ATS was not identified because of the low
abundance of these transcripts compared with that of the
COL3-APS RNAs. Like the other collagenase-3 transcripts,
the COL3-ATS transcripts were up-regulated in the osteo-
arthritic cells. The COL3-ATS-INT transcripts were not
detected and may be present in lower abundance than
COL3-ATS because of the splicing of the first intron.
The presence of a longer 5′-UTR in the COL3-ATS and
COL3-ATS-INT transcripts suggests the presence of cis-
elements upstream of the main transcription factor binding
sites (AP-1, PEA-3, OSE-2) that would be capable of
promoting transcription from an alternative initiation site.
Alternative promoter usage are known to regulate gene
expression by affecting the level of transcription initiation,
the translation efficiency of the mRNA produced, and the
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generation of protein isoforms differing at their amino
termini; alternative promoters may also respond differently
to the cellular environment66. Because the COL3-ATS
transcripts are probably derived from alternative promoter
elements, it is possible that these elements are activated
under certain physiological conditions such as those seen
in osteoarthritis, and the COL3-ATS transcripts are a way
to modulate the overall collagenase-3 production. Experi-
ments are underway to clone the upstream promoter
sequence and confirm the presence of an alternative
promoter.
In summary, we have shown that the collagenase-3 gene
is transcribed into various mRNAs species that arise from
an out-of-frame deletion, an alternative splicing event, and
different polyA and transcription initiation sites, and these
RNAs can be translated into proteins in a cellular environ-
ment. The transcripts are more abundant in samples from
osteoarthritic patients, indicating that these transcripts
could be synthesized in response to specific cellular envi-
ronments. Current studies are underway to over-express
the COL3-DEL and COL3-9B-2 proteins and assess their
activities and relevance to pathophysiological processes.
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